EUVIMEDEUVIMED entdecken
Crossref

The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

Ahmet Sarıcı, Mehmet Ali Erkurt, İrfan Kuku, Emin Kaya, İlhami Berber, Soykan Biçim, Emine Hidayet, Ahmet Kaya, Ömer Faruk Bahçecioğlu, Lokman Hekim Tanrıverdi, Sıdıka Gülkan Özkan

Istanbul Medical Journal · 31.05.2023 · 24 (2) · 216-220

DOI: 10.4274/imj.galenos.2023.98370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Istanbul Medical Journal, online erschienen am 31.05.2023. Verfasst von Ahmet Sarıcı und 10 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction:Chronic graft-versus host disease (GVHD) is a serious complication that develops in 35-50% of patients in the late period after allogeneic hematopoetic stem cell transplantation. About half of the patients are resistant to corticosteroids, which is the first-line treatment of chronic GVHD, and therefore new treatment options that can be effective in chronic GVHD are needed. In the present study, we aimed to share our experience with the use of ibrutinib therapy in patients with steroid-resistant chronic GVHD who have previously received multiple lines of systemic therapy.Methods:The characteristics and clinical outcomes of steroid-resistant chronic patients with GVHD receiving ibrutinib were retrospectively reviewed.Results:A total of 10 steroid resi-stant chronic patients with GVHD who received ibrutinib was included. While 50% of the patients had more than one organ involvement, 50% had a single organ involvement. The most commonly affected organs were the skin and liver. The patients received a median of three lines of systemic therapy before ibrutinib. After a median of 210 days of ibrutinib usage, the complete response rate of patients was 40% and the partial response rate was 40%. Corticosteroids were completely discontinued in 30% of patients after ibrutinib were initiated. Before ibrutinib, patients were given a median of 0.3 mg/kg methylprednisolone. The median methylprednisolone dose after ibrutinib was 0.03 mg/kg.Conclusion:Ibrutinib therapy causes a quite high overall response in steroid resistant chronic patients with GVHD and appears to be a good option in these patients.

Zitieren

APA

Sarıcı, A., Erkurt, M. A., Kuku, İ., Kaya, E., Berber, İ., Biçim, S., Hidayet, E., Kaya, A., Bahçecioğlu, Ö. F., Tanrıverdi, L. H., & Özkan, S. G. (2023). The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Istanbul Medical Journal, 24(2), 216-220. https://doi.org/10.4274/imj.galenos.2023.98370

Vancouver

Sarıcı A, Erkurt MA, Kuku İ, Kaya E, Berber İ, Biçim S, et al. The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Istanbul Medical Journal. 2023;24(2):216-220. doi:10.4274/imj.galenos.2023.98370

BibTeX
@article{Sarc2023,
  author = {Sarıcı, Ahmet and Erkurt, Mehmet Ali and Kuku, İrfan and Kaya, Emin and Berber, İlhami and Biçim, Soykan and Hidayet, Emine and Kaya, Ahmet and Bahçecioğlu, Ömer Faruk and Tanrıverdi, Lokman Hekim and Özkan, Sıdıka Gülkan},
  title = {The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience},
  journal = {Istanbul Medical Journal},
  year = {2023},
  volume = {24},
  number = {2},
  pages = {216--220},
  doi = {10.4274/imj.galenos.2023.98370}
}
Kostenlos starten →